Cost Considerations Drive Lean Technology in Biomanufacturing

May 15, 2017

Catherine Shaffer is a contributing writer to BioPharm International, cathshaffer@gmail.com.

Pharmaceutical Technology, Pharmaceutical Technology-05-15-2017, Volume 2017 eBook, Issue 1

Pages: s4-s7

Manufacturing for originator molecules is restricted by regulations, but drug makers can exploit newer technologies for the manufacture of biosimilars.

The approval of biosimilars for the US market has created a need for more efficient manufacturing processes.

Manufacturers are developing processes for cost efficiency and reliability using newer technology to compete with innovator products manufactured with legacy processes.

Innovations include more productive cell lines, single-use systems, and powerful analytical methods.

Download